RenovoRx, Inc.

Mr. Ryan  Witt

Senior Vice President and Head of Corporate Strategy & Partnerships

Mr. Shaun R. Bagai

Chief Executive Officer, Secretary & Director

Dr. Ramtin  Agah M.D.

Founder, Chairman of Board & Chief Medical Officer

Ms. Leesa  Gentry

Chief Clinical Officer

Mr. Ronald B. Kocak CPA, CGMA

Vice President, Controller & Principal Accounting Officer

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Operations to Achieve Next Interim Read-Out and Fund Current RenovoCath Commercialization Efforts LOS ALTOS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, today announced its financial results and operational highlights for the third quarter ended September 30, 2024.

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City. The conference will be held September 9-11, 2024, with Mr. Bagai's presentation on September 9, 2024, at 7:00 a.m. ET.

RenovoRx, Inc.RNXT

RenovoRx, Inc.
RNXT